icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Combination Therapy of Treatment-Na´ve and Nonresponder Patients With HCV Genotype 1 Infection With Daclatasvir (DCV; BMS-790052), an NS5A Replication Complex Inhibitor, in Combination With Peginterferon Alfa-2a and Ribavirin
 
 
  Reported by Jules Levin
AASLD Nov 5-9 2011 SF
 
Izumi N,1 Asahina Y,1 Yokosuka O,2 Imazaki F,2 Kawada N,3 Tamori A,3 Osaki Y,4 Kimura T,4 Yamamoto K,5 Takaki A,5 Sata M,6 Ide T,6 Ishikawa H,7 Ueki T,7 Yang R,8 McPhee F,8 Hughes E9 1Musashino Red Cross Hospital, Tokyo, Japan; 2Chiba University, Chiba, Japan; 3Osaka City University, Osaka, Japan; 4Osaka Red Cross Hospital, Osaka, Japan; 5Okayama University, Okayama, Japan; 6Kurume University, Kurume, Japan; 7Bristol-Myers KK, Tokyo, Japan; 8Bristol-Myers Squibb, Wallingford, CT; 9Bristol-Myers Squibb Research & Development, Princeton, NJ

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif